Experimental antibody trio takes on Hard-to-Treat melanoma
NCT ID NCT06784648
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new experimental antibody called BI-1607 alongside two existing immunotherapies (ipilimumab and pembrolizumab) in 35 people with advanced melanoma that has spread or cannot be removed. The goal is to see if the combination is safe and can shrink tumors. The study is currently active but not recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BI-1607 (an experimental antibody) combined with ipilimumab and pembrolizumab (immunotherapies)
What this could lead to
If successful, this combination could improve the immune system's ability to fight advanced melanoma that has stopped responding to current treatments.
What could go wrong
This is an early-phase trial with only 35 participants, so results may not apply broadly. The added drug may increase side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Universitatsmedizin Berlin
Berlin, Germany
-
Hospital Universitario Vall d'Hebron
Barcelona, Spain
-
Sarah Cannon Research Institute UK
London, Greater London, W1G 6AD, United Kingdom
-
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
-
University Hospital 12 de Octubre
Madrid, Spain
-
University Hospital Essen
Essen, Germany
-
University Hospital Heidelberg
Heidelberg, Germany
-
University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg and Clinical Cooperation Unit Dermato-Oncology(G300) German Cancer Research Center(DKFZ)
Mannheim, Germany
-
Velindre Cancer Centre
Cardiff, Wales, CF14 2TL, United Kingdom